medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2016, Number 3

Next >>

Residente 2016; 11 (3)

The RANK/RANKL/OPG system and its clinical implications in osteoporosis

Esparza-Guerrero Y, Nava-Valdivia CA, Saldaña-Cruz AM, Vásquez-Jiménez JC, Farias-Cuevas KP, Enriquez-Luna A, Gamez-Nava JI, Gonzalez-Lopez L, Corona-Sanchez EG

Language: Spanish
References: 28
Page: 99-104
PDF size: 282.15 Kb.


ABSTRACT

Bone is a connective tissue with high metabolic activity. It is under a constant process of renewal due to the participation of cells that comprise it, osteoblasts, osteoclasts and osteocytes, which are responsible for maintaining bone mass formation processes/resorption. Several factors influence the regulation or remodeling cycle imbalance, among which the intercellular RANK/RANKL/OPG protein system, responsible for the activation and differentiation of bone cells. Deregulation in some of its components may result in a decrease in bone mass and the development of osteoporosis. In Mexico, in 2010 the prevalence of osteoporosis was 8% in women over 40 years and is estimated that by 2020 the figure increased to 42%, which represents an increased risk of fractures. There are several treatments for the management of this condition, in this review the involvement of the components of the RANK/RANKL/OPG system and its utility as drug targets for the treatment of osteoporosis is addressed.


REFERENCES

  1. Liao X, Lu S, Zhuo Y, Winter C, Xu W, Li B et al. Bone physiology, biomaterial and the effect of mechanical/physical microenvironment on MSC osteogenesis: a tribute to Shu Chien’s 80th Birthday. Cell Mol Bioeng. 2011; 4 (4): 579-590.

  2. Neumann E, Schett G. Bone metabolism: molecular mechanisms. Z Rheumatol. 2007; 66 (4): 286-289.

  3. Eriksen EF. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. 2010; 11 (4): 219-227.

  4. Vidal C, Formosa R, Xuereb-Anastasi A. Functional polymorphisms within the TNFRSF11B (osteoprotegerin) gene increase the risk for low bone mineral density. J Mol Endocrinol. 2011; 47 (3): 327-333

  5. Soysa NS, Alles N. Osteoclast function and bone-resorbing activity: an overview. Biochem Biophys Res Commun. 2016; 476 (3): 115-120.

  6. Song R, Gu J, Liu X, Zhu J, Wang Q, Gao Q et al. Inhibition of osteoclast bone resorption activity through osteoprotegerin-induced damage of the sealing zone. Int J Mol Med. 2014; 34 (3): 856-862.

  7. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011; 17 (10): 1231-1234.

  8. Xiong J, O’Brien CA. Osteocyte RANKL: new insights into the control of bone remodeling. J Bone Miner Res. 2012; 27 (3): 499-505.

  9. Jilka RL, O’Brien CA, Bartell SM, Weinstein RS, Manolagas SC. Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms. J Bone Miner Res. 2010; 25 (11): 2427-2437.

  10. Iglesias L, Yeh JK, Castro-Magana M, Aloia JF. Effects of growth hormone on bone modeling and remodeling in hypophysectomized young female rats: a bone histomorphometric study. J Bone Miner Metab. 2011; 29 (2): 159-167.

  11. Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab. 2012; 23 (11): 576-581.

  12. Tu P, Duan P, Zhang RS, Xu DB, Wang Y, Wu HP et al. Polymorphisms in genes in the RANKL/RANK/OPG pathway are associated with bone mineral density at different skeletal sites in post-menopausal women. Osteoporos Int. 2015; 26 (1): 179-185.

  13. McGrath EE. OPG/RANKL/RANK pathway as a therapeutic target in cancer. J Thorac Oncol. 2011; 6 (9): 1468-1473.

  14. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014; 25 (10): 2359-2381.

  15. Clark P, Carlos F, Vázquez-Martínez JL. Epidemiology, costs and burden of osteoporosis in Mexico. Archives of Osteoporosis. 2010; 5 (1-2): 9-17.

  16. Silverman SL, Maricic M. Recent developments in bisphosphonate therapy. Semin Arthritis Rheum. 2007; 37 (1): 1-12.

  17. Wang Q, Chen Z, Huang Y, Li Q, Zhu L, Cai X et al. The relationship between osteoprotegerin gene polymorphisms and bone mineral density in Chinese postmenopausal women. Int Immunopharmacol. 2013; 17 (2): 404-407.

  18. Shang M, Lin L, Cui H. Association of genetic polymorphisms of RANK, RANKL and OPG with bone mineral density in Chinese peri- and postmenopausal women. Clin Biochem. 2013; 46 (15): 1493-1501.

  19. Boronova I, Bernasovska J, Macekova S, Petrejcikova E, Tomkova Z, Kloc J et al. TNFRSF11B gene polymorphisms, bone mineral density, and fractures in Slovak postmenopausal women. J Appl Genet. 2015; 56 (1): 57-63.

  20. Mencej-Bedrac S, Prezelj J, Marc J. TNFRSF11B gene polymorphisms 1181G > C and 245T > G as well as haplotype CT influence bone mineral density in postmenopausal women. Maturitas. 2011; 69 (3): 263-267.

  21. Kim JG, Kim JH, Kim JY, Ku SY, Jee BC, Suh CS et al. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappa B (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause. 2007; 14 (5): 913-918.

  22. Henriksen K, Byrjalsen I, Andersen JR, Bihlet AR, Russo LA, Alexandersen P et al. A randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy and safety of oral salmon calcitonin in the treatment of osteoporosis in postmenopausal women taking calcium and vitamin D. Bone. 2016; 91: 122-129.

  23. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006; 354 (8): 821-831.

  24. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361 (8): 756-765.

  25. Chypre M, Seaman J, Cordeiro OG, Willen L, Knoop KA, Buchanan A et al. Characterization and application of two RANK-specific antibodies with different biological activities. Immunol Lett. 2016; 171: 5-14.

  26. Blake GM, Fogelman I. The clinical role of dual energy X-ray absorptiometry. Eur J Radiol. 2009; 71 (3): 406-414.

  27. Sasso GR, Florencio-Silva R, Simões RS, Baracat MC, Soares-Junior JM, Baracat EC. Elevated serum osteoprotegerin levels in women: friend or foe? Rev Assoc Med Bras. 2015; 61 (6): 524-529.

  28. Kostenuik PJ, Bolon B, Morony S, Daris M, Geng Z, Carter C et al. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone. 2004; 34 (4): 656-664.




2020     |     www.medigraphic.com